2022-08 – Q2 2022 Reporting

  • Still low number of patients entered the study in Q2-2022.
  • A new Australian based CRO for SER150 CL-009 clinical study will continue the study on Serodus behalf.
  • Complete transfer expected to be finalized mid Q3-2022.
  • Australian ethical committee has approved increasing dosing period from 3 to 6 months.

Read more here